Not Signed In - Human Genome Sciences Initiates Phase 3 Clinical Trial Of Albuferon(R) In Combination With Ribavirin For Patients With Chronic Hepatitis C
Wed, 20 Dec 2006 08:00 AM EST
... Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has initiated dosing in ACHIEVE 1, one of two pivotal Phase 3 clinical trials of Albuferon(R) (albinterferon alpha 2b) in combination with ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C. [click link for full article] ...
Related Topics
- Clinical Trials
- Genes and Gene Therapy
- Hepatitis C
- Hepatitis B
- Ribavirin and Interferon alfa-2b, recombinant
- Hepatitis A
- Psychopharmacology
- Human Genome Epidemiology Network
- Hepatitis
- Autoimmune Hepatitis
- Hepatitis A and Hepatitis B Vaccine
- Hepatitis A Vaccine
- Human Papilloma Virus
- Hepatitis B Vaccine
- Hepatitis B Immune Globulin
- Chronic Fatigue Syndrome
- Growth Hormones
- Growth Hormone
- Chronic Pain
- Pain - Chronic
email this page
print this page
bookmark this page
feedback on this page
